Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating the effect of dalcetrapib on cardiovascular risk in people recently hospitalized for acute coronary syndrome ACS who have a specific genetic profile AA genotype. This phase 3, randomized, double-blind, placebo-controlled study focuses on adults aged 45 years and older, aiming to assess the time to first occurrence of fatal or non-fatal myocardial infarction over an average of 30 months from randomization. The study will continue until around 200 participants experience a primary event, or until stopped at an interim analysis. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily, two 300 mg tablets or matching placebo tablets once daily. Screening includes genetic testing for the AA genotype using a specialized Genotype Assay Test. Enrollment can begin during hospitalization or after discharge, but randomization must occur within 12 weeks of the ACS event. After randomization, follow-up visits will be virtual when possible or in clinic every three months until the study ends. Assessments will continue every three months for participants who stop the study medication early. Participants will undergo medical history review and genetic testing before enrollment. During the study, researchers will monitor cardiovascular events such as heart attacks and strokes through regular assessments every three months. Safety evaluations and collection of study endpoints will continue for the duration of participation, which may last approximately 30 months or until the study stops. This includes ongoing monitoring for adverse effects and overall health status.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Artix Thrombectomy System, a device designed for removing arterial blockages in the lower limbs. This study focuses on patients with acute lower limb arterial occlusions occurring below the inguinal ligament, with symptoms lasting 14 days or less. The trial is a post-market, prospective, multicenter, single-arm study sponsored by Inari Medical that aims to gather important data on this treatment approach. Participants receive treatment using the Artix Thrombectomy System to non-surgically remove arterial emboli and thrombi from the lower extremities. This device is used on target lesions in native vessels sized between 3 mm and 8 mm, classified under Rutherford categories I, IIa, or IIb. The study monitors immediate effectiveness after the procedure and safety within 48 hours, with no comparison to other treatments. During the study, participants undergo assessments immediately following treatment and at follow-up visits up to one month later. Researchers will evaluate outcomes such as distal embolization serious adverse events during the procedure, all-cause mortality, limb salvage, and amputation-free survival at one month. Participants are monitored closely to understand the devices performance and safety over the study period, which lasts until October 2029.
Actively Recruiting
Researchers are evaluating the Thor system in adults aged 18 years and older who have new, untreated calcified blockages in leg arteries caused by peripheral artery disease PAD. The study aims to determine whether the Thor system is safe and effective for treating these lesions. Patients experience leg pain due to poor blood flow, and the study will observe how the Thor system works in this setting. All participants will receive treatment using the Thor laser atherectomy system, which targets calcified lesions to improve blood flow. During the procedure, doctors may also use additional devices such as angioplasty balloons, drug-coated balloons, stents, and clot-collecting filters if needed. The procedure includes x-ray imaging, and patients will be monitored closely until discharge or for up to 24 hours after treatment. Participants will have follow-up visits at discharge, 30 days, 6 months, and 12 months after the procedure. These visits include medical history reviews, physical exams of the legs, blood flow tests using arm and leg blood pressure comparisons, ultrasound imaging, and questionnaires about walking ability and quality of life. The study will measure outcomes such as freedom from major adverse events, procedural success, lesion openness, and improvements in walking and health surveys over one year.
Actively Recruiting
Researchers are evaluating the TIVUS Renal Denervation System for people with hypertension, focusing on its safety and additional effects when used alongside or instead of antihypertensive medications. The study includes adults aged 22 to 75 who have uncontrolled or controlled high blood pressure and are willing to stop their blood pressure medications for a specified period around the procedure. This international, randomized, double-blind, sham-controlled trial aims to compare TIVUS with a minimally invasive sham procedure to better understand its role in managing hypertension. Participants undergo a renal artery catheterization where the TIVUS device uses ultrasound energy to target nerves around the renal arteries. Those randomized to the sham group receive an angiogram serving as a placebo procedure. All subjects stop their antihypertensive drugs for a 4-week washout before and 2 months after the procedure. After 2 months, participants with uncontrolled hypertension restart medications following a set protocol. Some patients in the sham group with uncontrolled blood pressure at 6 months may choose to receive the TIVUS treatment. Follow-up for those treated with TIVUS lasts up to 36 months. During the study, participants will have regular blood pressure measurements taken through ambulatory, home, and office monitoring. Researchers will assess daytime and 24-hour blood pressure changes from before treatment to 2 months post-procedure, as well as track major adverse events up to 6 months. The study will also monitor blood pressure targets, reductions at various time points, and safety outcomes. Participants are evaluated at scheduled visits for up to three years to understand the long-term effects and safety of the TIVUS system.